These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

558 related items for PubMed ID: 21531154

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Combined iron chelation therapy.
    Galanello R, Agus A, Campus S, Danjou F, Giardina PJ, Grady RW.
    Ann N Y Acad Sci; 2010 Aug; 1202():79-86. PubMed ID: 20712777
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Hypogonadism, diabetes mellitus, hypothyroidism, hypoparathyroidism: incidence and prevalence related to iron overload and chelation therapy in patients with thalassaemia major followed from 1980 to 2007 in the Ferrara Centre.
    Gamberini MR, De Sanctis V, Gilli G.
    Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():158-69. PubMed ID: 19337172
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The safety, tolerability, and efficacy of a liquid formulation of deferiprone in young children with transfusional iron overload.
    ElAlfy MS, Sari TT, Lee CL, Tricta F, El-Beshlawy A.
    J Pediatr Hematol Oncol; 2010 Nov; 32(8):601-5. PubMed ID: 20921906
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Longitudinal changes of endocrine and bone disease in adults with β-thalassemia major receiving different iron chelators over 5 years.
    Poggi M, Sorrentino F, Pugliese P, Smacchia MP, Daniele C, Equitani F, Terlizzi F, Guitarrini MR, Monti S, Maffei L, Losardo A, Pasin M, Toscano V.
    Ann Hematol; 2016 Apr; 95(5):757-63. PubMed ID: 26957357
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with beta-thalassemia major.
    Wu KH, Chang JS, Tsai CH, Peng CT.
    Ann Hematol; 2004 Jul; 83(7):471-3. PubMed ID: 14658011
    [Abstract] [Full Text] [Related]

  • 20. Role of vitamin C as an adjuvant therapy to different iron chelators in young β-thalassemia major patients: efficacy and safety in relation to tissue iron overload.
    Elalfy MS, Saber MM, Adly AA, Ismail EA, Tarif M, Ibrahim F, Elalfy OM.
    Eur J Haematol; 2016 Mar; 96(3):318-26. PubMed ID: 26018112
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.